1427-P: Glycemic Trend in Metropolitan vs. Nonmetropolitan Cities of India—Three-Year Follow-up Results of LANDMARC

Glycemic trends in type 2 diabetes (T2D) participants from Indian metropolitan and non-metropolitan cities have been less studied and hence, were evaluated in the LANDMARC trial (a 3-year nationwide prospective observational study; CTRI/2017/05/008452). A total of 5273 of 6222 evaluable participants with T2D taking ≥2 antihyperglycemic medications (with/without glycemic control) completed the 3-year follow-up visit. Age, T2D duration, and baseline A1C were comparable across participants from metropolitan and non-metropolitan cities. At 3-years, a decrease in all glycemic parameters was noted. FPG levels from baseline improved more in participants from metropolitan than non-metropolitan cities (mean [95% CI]: −21.6 mg/dL [−25.2, −18.0] vs. −15.8 mg/dL [−18.8, −12.8]; p=0.0149). No significant difference in change from baseline between metropolitan and non-metropolitan cities was noted for A1C (p=0.2070) and PPG (p=0.3592) (Table). Almost one third of the participants in metropolitan (492/1534 [32.07%]) and non-metropolitan (864/2166 [39.89%]) cities achieved glycemic control (A1C <7%). Overall, participants from both metropolitan and non-metropolitan cities showed marked improvement in all glycemic parameters from baseline to the end of 3 years. These results help compare the longitudinal glycemic patterns among participants with T2D in cities across India. Disclosure A.Unnikrishnan: Speaker's Bureau; Sanofi, AstraZeneca, Boehringer-Ingelheim, Intas Pharmaceuticals Ltd. A.Sugumaran: Employee; Sanofi. A.Satpathy: Employee; Sanofi. A.Gadekar: Employee; Sanofi. S.K.Menon: Employee; Sanofi. R.Neogi: Employee; Sanofi. D.Chodankar: Employee; Sanofi. C.Trivedi: None. S.Wangnoo: None. A.H.Zargar: None. N.Rais: Advisory Panel; Bayer Consumer Care AG, Board Member; Abbott, Biocon. A.K.Das: n/a. S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. A.Mithal: Advisory Panel; Eris Lifesciences Ltd., Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited, Research Support; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim, AstraZeneca, Sun Pharmaceutical Industries Ltd., Novartis. S.Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. K.Kumar: None. H.Thacker: None. B.Sethi: None. S.Chowdhury: None. Funding Sanofi India